SEL24/MEN1703 in Patients With Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the clinical trial is to identify the maximum tolerated dose of SEL24/MEN1703
and to further investigate its safety profile in patients with Acute Myeloid Leukemia.